Search filters

PDS Pathology Data Systems AG sold to Instem plc

Instem plc, a leading provider of IT solutions and services to the global life sciences market, has acquired its Swiss competitor PDS Pathology Data Systems AG, with offices in the United States and Japan, at an enterprise value of CHF 14.25m.

Massive claims and allegations against Swiss bank fended off

The VISCHER Dispute Resolution team led by Thomas Weibel successfully defended a Swiss bank in a multi-front battle.

Successful collection of commodities trading Award claim in Switzerland

The VISCHER dispute resolution team successfully enforced an ICC arbitral award rendered in London and stemming from international commodity trading in Switzerland.

evitria Group sold to Atlas Antibodies, Sweden

The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies, Sweden. The transaction was completed on August 5, 2021.

Rigeto portfolio company Swissphone acquires instaSOLUTION AG

Rigeto portfolio company Swissphone acquires instaSOLUTION AG. The transaction was completed on July 16, 2021.

RELIEF closes CHF 15m private placement

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company, has entered into a binding agreement with two U.S. institutional investors to purchase in a private placement Relief shares of CHF 15m total.

RELIEF issues 1bn new shares from authorized capital

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company, has issued 1,000,000,000 additional registered shares out of the authorized share capital approved by the Annual General Meeting on 18 June 2021.

MEININGER hotel openings in Zurich and Geneva

International hotel group MEININGER manages its successful market entry in Switzerland and opens new hotels in Zurich and Geneva.

Kuros Biosciences enters royalty purchase agreement with Xoma

Kuros to receive USD 7m up front and retain the potential to receive up to USD 166.5m in future revenues under a royalty purchase agreement with XOMA Corporation

TargImmune financing round with CHF 17.7m.

TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m.

You are currently offline. Some pages or content may fail to load.